olmesartan medoxomil, amlodipine and hydrochlorothiazide
OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE (olmesartan medoxomil, amlodipine and hydrochlorothiazide) by Hetero is medoxomil, amlodipine and hydrochlorothiazide target three separate mechanisms involved in blood pressure regulation. Approved for hypertension, alone, other antihypertensive agents and 1 more indications. First approved in 2025.
Drug data last refreshed 1w ago
medoxomil, amlodipine and hydrochlorothiazide target three separate mechanisms involved in blood pressure regulation. Specifically, amlodipine blocks the contractile effects of calcium on cardiac and vascular smooth muscle cells; olmesartan medoxomil blocks the vasoconstriction and sodium retaining…
Worked on OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE at Hetero? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Thiazide Diuretic
Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide Combination Therapy in Patients With Hypertension Not Controlled With Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy